PAR 1.92% 25.5¢ paradigm biopharmaceuticals limited..

Where we at?, page-576

  1. 4,172 Posts.
    lightbulb Created with Sketch. 6645
    ShareTurkey:


    Nah definitely not a write off...they had some really good data in MPS VI....MPS I was very good data as well, see post below this one on MPS I.

    MPS VI a few highlights:


    The 9-HPT involves manipulating pegs within a pegboard as quickly and accurately as possible, providing a quantitative measure of upper extremity function and fine motor control. Results are reported for both the dominant hand and the non-dominant hand. Participants receiving iPPS in the phase 2 clinical trial demonstrated greater improvement than placebo in the 9-hole peg test from baseline to week 25 on at least one hand.

    PGIC:

    The childhood health assessment questionnaire (CHAQ) disability index score, where 0 =no disability and 3 = very severe disability, demonstrated a response to treatment. When compared to baseline, the change in disability score for the PPS group was -0.350 versus placebo -0.125, where a minimally clinically important difference for improvements -0.188.


    GAGS:

    Mozz view - Yes GAGS results here weren't anything special, they were in MPS I, could be ERTS interplay. (MPS I was Bone Marrow Treatment).

    At the end of the day, in my view, to progress the MPS program a Global Phase 3 needs to be conducted. PAR will no doubt focus squarely on OA so it doesn't tie up further resources in terms of staff and cash. I think it's prudent to do this and revisit the MPS program with a suitable partner at a later stage.



 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
25.5¢
Change
-0.005(1.92%)
Mkt cap ! $89.19M
Open High Low Value Volume
27.0¢ 27.0¢ 25.5¢ $261.4K 990.7K

Buyers (Bids)

No. Vol. Price($)
1 9999 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 9445 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.